Tin Mesoporphyrin IX (chloride) (Synonyms: NSC 267099,SnMP) |
| Catalog No.GC17594 |
Tin Mesoporphyrin IX (chloride) (Stannsoporfin) is a heme oxygenase (HO) inhibitor being developed for the prevention of hyperbilirubinemia in infants at risk of developing jaundice, extracted from patent WO2011103196A1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 106344-20-1
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Ki = 14 nM
Tin Mesoporphyrin IX is a potent and competitive inhibitor of heme oxygenase (HO) activity.
Heme oxygenase or haem oxygenase (HO) is an enzyme catalyzing the degradation of heme. This produces biliverdin, ferrous iron, and carbon monoxide. There is limited evidence that levels of heme oxygenase are positive predictors of metabolic disease, insulin resistance, and metaflammation.
In vitro: Previous study found that Tin Mesoporphyrin IX was a potent competitive in-vitro inhibitor of enzyme activity when it was incubated with rat splenic microsomal heme oxygenase, with a Ki of 0.014 microM [1].
In vivo: Animal study showed that Tin Mesoporphyrin IX at 1 pmol/kg body wt could inhibit hepatic, renal, and splenic heme oxygenase activity in adult animals for extended periods of time. Tin Mesoporphyrin IX at 1 pmol/kg body wt also prevented the transient increase in serum bilirubin 24 h after birth in the rat neonate and significantly reduced the levels of serum bilirubin in aminolevulinic acid induced hyperbilirubinemia in the 7-day-old suckling neonate. Moreover, it was found that the tissue heme oxygenase activity decreased in both animal models of hyperbilirubinemia. Tin Mesoporphyrin IX treatment resulted in a prolonged increase in the heme saturation of hepatic tryptophan pyrrolase [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Drummond, G. S.,Galbraith, R.A.,Sardana, M.K., et al. Reduction of the C2 and C4 vinyl groups of Sn-protoporphyrin to form Sn-mesoporphyrin markedly enhances the ability of the metalloporphyrin to inhibit in vivo heme catabolism. Archives of Biochemistry and Biophysics 255(1), 64-74 (1987).
| Cas No. | 106344-20-1 | SDF | |
| Synonyms | NSC 267099,SnMP | ||
| Chemical Name | (OC-6-13)-dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-κN21,κN22,κN23,κN24]-stannate(2-), dihydrogen | ||
| Canonical SMILES | [Cl-][Sn+4]123([N-]4C5=C(CCC([O-])=O)C(C)=C4C=C(C(CC)=C6C)[N]1=C6C=C(C(CC)=C7C)[N-]2C7=CC8=[N]3C(C(CCC([O-])=O)=C8C)=C5)[Cl-].[H+].[H+] | ||
| Formula | C34H34Cl2N4O4Sn • 2H | M.Wt | 754.3 |
| Solubility | ≤0.5mg/ml in DMSO;1mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3257 mL | 6.6287 mL | 13.2573 mL |
| 5 mM | 0.2651 mL | 1.3257 mL | 2.6515 mL |
| 10 mM | 0.1326 mL | 0.6629 mL | 1.3257 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *